Citations

Clear

3057 citation(s) found for "Cd, Johnson".

NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
Jonasch, Eric, Alva, Ajjai , Bagshaw, H.P. , Costello, Brian A. , Derweesh, Ithaar , Desai, Arpita, Ged, Yasser , Johnson, Michael P. , King, Jennifer , Kyriakopoulos, Christos E. , Lara, Primo N. , Lau, Clayton, Lewis, Bryan , Mortazavi, Amir , Ponsky, Lee , Ramalingam, Sundhar, Shuch, Brian , Smith, Zachary L. , Sosman, Jeffrey A. , Zibelman, Matthew R. , Schonfeld, Ryan, Stein, MaryElizabeth , Gurski, Lisa A., Motzer, Robert J. , Agarwal, Neeraj , Baine, Michael J. , Beckermann, Kathryn E. , Carlo, Maria I. , Choueiri, Toni K. , George, Saby , Gore, John L. , Gunn, Andrew, Haas, Naomi B , Johnson, Michael, Kapur, Payal , King, Jennifer, Lam, Elaine T. , Madoff, David C. , Manley, Brandon J. , Michaelson, M. Dror , Sweis, Randy F.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 23, 2024 | Volume: 22 | Issue: 1 | Pages: 4-16

10.6004/jnccn.2024.0008 | PMID 38394781 Get It

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on the systemic therapy options for patients with advanced RCC and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Kidney Cancer.
Use of Transesophageal Echocardiography for Liver Transplantation: A Global Comparison of Practice From the ILTS, SATA, and LICAGE
Wagener, Gebhard , Johnson, Taylor , Pan, Terry Ling Te , Marchi, Lorenzo De , Bezinover, Dmitri , Zerillo, Jeron , Chadha, Ryan , Blasi, Annabel

Mayo Clinic

Transplantation | February 22, 2024 | Volume: 108 | Issue: 7 | Pages: 1570-1583

10.1097/tp.0000000000004943 | PMID 38383955 Get It

Background. Anesthesiologists frequently use intraoperative transesophageal echocardiography (TEE) to aid in the diagnosis and management of hemodynamic problems during liver transplantation (LT). Although the use of TEE in US centers continues to increase, data regarding international use are lacking. Methods. This prospective, global, survey-based study evaluates international experience with TEE for LT. Responses from 252 LT (105 US and 147 non-US) centers representing 1789 anesthesiologists were analyzed. Results. Routine use of TEE in the United States has increased in the last 5 y (from 37% to 47%), but only 21% of non-US LT anesthesiologists use TEE routinely. Lack of training (44% US versus 70% non-US) and equipment (9% non-US versus 34% US) were cited as obstacles. Most survey participants preferred not to perform a complete cardiac examination but rather use only 6 of 11 basic views. Although non-US LT anesthesiologists more frequently had additional clinical training than their US counterparts, they had less TEE experience (13% versus 44%) and less frequently, TEE certification (22% versus 35%). Most LT anesthesiologists agreed that TEE certification is essential for proficiency. Of all respondents, 89% agreed or strongly agreed that TEE provides valuable information needed for immediate clinical decision-making, and >86% agreed or strongly agreed that that information could not be derived from other sources. Conclusions. The use of TEE for LT surgery in the US LT centers is currently higher compared with non-US LT centers. This may become a standard monitoring modality during LT in the near future.
Presenilin‐1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage
Joseph‐Mathurin, Nelly , Feldman, Rebecca L. , Lu, Ruijin , Shirzadi, Zahra , Toomer, Carmen, Clair, Junie R. Saint, Ma, Yinjiao , Strain, Jeremy F. , Kilgore, Collin , Chen, Charles D., Gordon, Brian A. , Chen, Gengsheng , Hornbeck, Russ C. , Massoumzadeh, Parinaz , Wang, Qing , Li, Yan , Wang, Guoqiao , Keefe, Sarah , Schultz, Stephanie A. , Preboske, Gregory M., Jack, Clifford R. , Ances, Beau M. , Berman, Sarah , Day, Gregory S. , Fox, Nick C. , Fulham, Michael , Ghetti, Bernardino , Johnson, Keith A. , Xiong, Chengjie , Oh, Hwamee , Perrin, Richard J. , Ringman, John M. , Saykin, Andrew J. , Supnet, Charlene , Vöglein, Jonathan , Yakushev, Igor , Morris, John C. , Chhatwal, Jasmeer P. , Network, for the Dominantly Inherited Alzheimer, Jack, Clifford R , Gordon, Brian A , Saykin, Andrew J , Day, Gregory S , Vöglein, Jonathan , Joseph-Mathurin, Nelly , Xiong, Chengjie , Chen, Charles D , Ances, Beau M , Fox, Nick C , Morris, John C , Ghetti, Bernardino F , Supnet-Bell, Charlene , Berman, Sarah , Clair, Junie Saint, McKay, Nicole S. , Friedrichsen, Karl A. , McCullough, Austin , Li, Yan, Cruchaga, Carlos , Llibre‐Guerra, Jorge J. , Allegri, Ricardo , Brooks, William S. , Cash, David M. , Jucker, Mathias , Klunk, William E. , Fougère, Christian la , Niimi, Yoshiki , Reischl, Gerald , Schofield, Peter R. , Su, Yi , Brickman, Adam M. , McDade, Eric , Xiong, Chengjie , Bateman, Randall J. , Benzinger, Tammie L.S. , Network, for the Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | February 21, 2024 | Volume: 20 | Issue: 4 | Pages: 2680-2697

10.1002/alz.13729 | PMID 38380882 Get It

AbstractINTRODUCTIONAmyloidosis, including cerebral amyloid angiopathy, and markers of small vessel disease (SVD) vary across dominantly inherited Alzheimer's disease (DIAD) presenilin‐1 (PSEN1) mutation carriers. We investigated how mutation position relative to codon 200 (pre‐/postcodon 200) influences these pathologic features and dementia at different stages.METHODSIndividuals from families with known PSEN1 mutations (n = 393) underwent neuroimaging and clinical assessments. We cross‐sectionally evaluated regional Pittsburgh compound B‐positron emission tomography uptake, magnetic resonance imaging markers of SVD (diffusion tensor imaging‐based white matter injury, white matter hyperintensity volumes, and microhemorrhages), and cognition.RESULTSPostcodon 200 carriers had lower amyloid burden in all regions but worse markers of SVD and worse Clinical Dementia Rating® scores compared to precodon 200 carriers as a function of estimated years to symptom onset. Markers of SVD partially mediated the mutation position effects on clinical measures.DISCUSSIONWe demonstrated the genotypic variability behind spatiotemporal amyloidosis, SVD, and clinical presentation in DIAD, which may inform patient prognosis and clinical trials.Highlights Mutation position influences Aβ burden, SVD, and dementia. PSEN1 pre‐200 group had stronger associations between Aβ burden and disease stage. PSEN1 post‐200 group had stronger associations between SVD markers and disease stage. PSEN1 post‐200 group had worse dementia score than pre‐200 in late disease stage. Diffusion tensor imaging‐based SVD markers mediated mutation position effects on dementia in the late stage.
Reversibility of Bicalutamide PSMA PET-Positive Gynecomastia With Androgen Deprivation Therapy
Muniz, Miguel, Orme, Jacob J. , Johnson, Geoffrey B. , Johnson, Geoffrey B , Childs, Daniel S. , Sartor, Oliver

Mayo Clinic

Clinical Nuclear Medicine | February 20, 2024 | Volume: 49 | Issue: 4 | Pages: e164-e165

10.1097/rlu.0000000000005084 | PMID 38377363 Get It

Abstract A 78-year-old man receiving bicalutamide for prostate cancer was referred for a PSMA PET/CT scan to evaluate his gradually rising prostate-specific antigen level. The PSMA PET/CT revealed gynecomastia with radiotracer uptake in bilateral breast parenchyma, a known but rarely reported effect of bicalutamide monotherapy. This scan also demonstrated metastatic progression of his disease in bone and lymph nodes, and he was started on leuprolide injections. Three months after a decrease in his testosterone level, the radiotracer uptake in his breast tissue had resolved, demonstrating that PSMA-avid bicalutamide-induced gynecomastia is reversible.
Robotics in Massage: A Systematic Review
Yang, Juan , Lim, Kia Hui , Mohabbat, Arya B. , Fokken, Shawn C. , Johnson, Devan E., Calva, Jason J., Do, Alexander , Mueller, Michael , Chon, Tony Y. , Bauer, Brent A.

Mayo Clinic

Health Services Research and Managerial Epidemiology | February 20, 2024 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/23333928241230948 | PMID 38379713 Get It

Background Over the past few years, a growing number of studies have explored massage robots. However, to date, a dedicated systematic review focused solely on robot-assisted massage has not been conducted. Objective To systematically identify and summarize evidence from studies concerning robot-assisted massage in healthcare settings. Methods An extensive literature search, involving electronic databases Ovid and Scopus, was conducted from the inception of the databases up to March 2023. This systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, and relevant papers were chosen based on the predefined inclusion criteria. Given the substantial methodological diversity among the included studies, a qualitative analysis was conducted. Results Seventeen studies met the inclusion criteria, comprising 15 preliminary trials, one quasi-experimental study, and one randomized controlled trial. Approximately 29% of the studies focused on the application of robotic massage for patients, 24% targeted both healthy volunteers and patients, and the remaining 47% were preclinical trials assessing the effectiveness of robotic massage solely on healthy volunteers. Primary interventions included robotic massage for oral rehabilitation, scalp massage, low back massage, shoulder massage, and full-body massage. All studies provided evidence that robotic massage interventions can enhance health and well-being, indicating a promising future for the integration of robotics in the field of massage therapy. Conclusions In general, robotic massage interventions offer physical and mental health benefits. Robot-assisted massage may be integrated into care provision as an adjunct to enhance human well-being. Nonetheless, further research is needed to confirm these findings.
The spectrum of concern for medical child abuse among adolescents with chronic pain due to central sensitisation
Johnson, Katie L. , Tham, See Wan , Brown, Emily , Walco, Gary A. , Wiester, Rebecca T., Wilkins, Stephanie N., Campbell, Kristine A. , Feldman, Kenneth W.

Mayo Clinic

Child Abuse Review | February 19, 2024 | Volume: 33 | Issue: 1 | Pages: No page available

10.1002/car.2861 | PMID 39308529 Get It

AbstractAdolescents with chronic pain can at times present with disability out of proportion to diagnostic workup. This is also a defining feature of medical child abuse (MCA). The aim of this study was to identify themes from the clinical narratives of adolescents with chronic pain that may indicate concern for MCA. This qualitative, retrospective study at an academic children's hospital between 2011 and 2019 identified 37 adolescents aged 13–18 years old with chronic pain and varying levels of concern for MCA. Conventional, inductive content analysis was used to identify themes from the medical records of all patients, which were reviewed by an interdisciplinary panel of experts. Themes were organised into three tiers related to the level of concern for MCA: ‘Green zone’ themes including fatigue or sleep problems, psychosocial distress, and social withdrawal were common among all patients. ‘Yellow zone’ themes including fragmented care, caregiver catastrophising, caregiver misrepresentation, medical provider exasperation, and sick identity were more common among patients in whom medical providers raised concern for MCA. A single ‘red zone’ theme, reportable harm to the child, was only present in patients diagnosed by a child abuse paediatrician as having MCA. A visual display of the results is provided for further research and clinical application.
The relevance of biologically effective dose for pain relief and sensory dysfunction after Gamma Knife radiosurgery for trigeminal neuralgia: an 871-patient multicenter study
Warnick, Ronald E. , Adam, Elizabeth , Iorio‐Morin, Christian , Leduc, William, Hamel, Andréanne, Johnson, Sarah E. , Bydon, Mohamad , Niranjan, Ajay , Lunsford, L. Dade , Wei, Zhishuo , Waite, Kaitlin, Jose, Shalini, Peker, Selçuk , Samanci, Mustafa Yavuz, Tek, Ece, Pikis, Stylianos , Sheehan, Jason P. , Kumar, Narendra , Bernstein, Kenneth , Ahorukomeye, Peter , Kshettry, Varun R. , Hernández, Wenceslao, Urgošík, Dušan, Lee, John Y. K., Patel, Samir , Kusyk, Dorian , Shepard, Matthew J., Samancı, Yavuz , Paddick, Ian , Mathieu, David , Mantziaris, Georgios , Tripathi, Manjul , Alzate, Juan Diego , Speckter, Herwin , Liščák, Roman , Yang, Andrew I. , Kondziolka, Douglas

Mayo Clinic

Journal of Neurosurgery | February 17, 2024 | Volume: 141 | Issue: 2 | Pages: 461-473

10.3171/2023.12.jns231569 | PMID 38364220 Get It

OBJECTIVE Recent studies have suggested that biologically effective dose (BED) is an important correlate of pain relief and sensory dysfunction after Gamma Knife radiosurgery (GKRS) for trigeminal neuralgia (TN). The goal of this study was to determine if BED is superior to prescription dose in predicting outcomes in TN patients undergoing GKRS as a first procedure. METHODS This was a retrospective study of 871 patients with type 1 TN from 13 GKRS centers. Patient demographics, pain characteristics, treatment parameters, and outcomes were reviewed. BED was compared with prescription dose and other dosimetric factors for their predictive value. RESULTS The median age of the patients was 68 years, and 60% were female. Nearly 70% of patients experienced pain in the V2 and/or V3 dermatomes, predominantly on the right side (60%). Most patients had modified BNI Pain Intensity Scale grade IV or V pain (89.2%) and were taking 1 or 2 pain medications (74.1%). The median prescription dose was 80 Gy (range 62.5–95 Gy). The proximal trigeminal nerve was targeted in 77.9% of cases, and the median follow-up was 21 months (range 6–156 months). Initial pain relief (modified BNI Pain Intensity Scale grades I–IIIa) was noted in 81.8% of evaluable patients at a median of 30 days. Of 709 patients who achieved initial pain relief, 42.3% experienced at least one pain recurrence after GKRS at a median of 44 months, with 49.0% of these patients undergoing a second procedure. New-onset facial numbness occurred in 25.3% of patients after a median of 8 months. Age ≥ 63 years was associated with a higher probability of both initial pain relief and maintaining pain relief. A distal target location was associated with a higher probability of initial and long-term pain relief, but also a higher incidence of sensory dysfunction. BED ≥ 2100 Gy2.47 was predictive of pain relief at 30 days and 1 year for the distal target, whereas physical dose ≥ 85 Gy was significant for the proximal target, but the restricted range of BED values in this subgroup could be a confounding factor. A maximum brainstem point dose ≥ 29.5 Gy was associated with a higher probability of bothersome facial numbness. CONCLUSIONS BED and physical dose were both predictive of pain relief and could be used as treatment planning goals for distal and proximal targets, respectively, while considering maximum brainstem point dose < 29.5 Gy as a potential constraint for bothersome numbness.
Transforming Outcomes of Spine Surgery—Exploring the Power of Enhanced Recovery After Surgery Protocol: A Systematic Review and Meta-Analyses of 15 198 Patients
Magableh, Hamzah M , Ibrahim, Sufyan , Pennington, Zach , Nathani, Karim Rizwan , Johnson, Sarah E. , Freedman, Brett A. , Bydon, Mohamad , Pennington, Zachary, Katsos, Konstantinos, Pennington, Zach , Nathani, Karim Rizwan , Ibrahim, Sufyan , Katsos, Konstantinos

Mayo Clinic

Neurosurgery | February 15, 2024 | Volume: 95 | Issue: 1 | Pages: 3-25

10.1227/neu.0000000000002865 | PMID 38358272 Get It

BACKGROUND AND OBJECTIVES: Enhanced recovery after surgery (ERAS) protocols aim to optimize patient outcomes by reducing the surgical stress response, expediting recovery, and reducing care costs. We aimed to evaluate the impact of implementing ERAS protocols on the perioperative surgical outcomes and financial implications associated with spine surgeries. METHODS: A systematic review and meta-analysis of peer-reviewed studies directly comparing outcome differences between spine surgeries performed with and without utilization of ERAS pathways was conducted along Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. RESULTS: Of 676 unique articles identified, 59 with 15 198 aggregate patients (7748 ERAS; 7450 non-ERAS) were included. ERAS-treated patients had shorter operative times (mean difference [MD]: 10.2 mins; P < .01), shorter hospitalizations (MD: 1.41 days, P < .01), fewer perioperative complications (relative risk [RR] = 0.64, P < .01), lower postoperative opioid use (MD of morphine equivalent dose: 164.36 mg; P < .01), and more rapid mobilization/time to first out-of-bed ambulation (MD: 0.92 days; P < .01). Spine surgeries employing ERAS were also associated with lower total costs (MD: $1140.26/patient; P < .01), especially in the United States (MD: $2869.11/patient, P < .01) and lower postoperative visual analog pain scores (MD = 0.56, P < .01), without any change in odds of 30-day readmission (RR: 0.80, P = .13) or reoperation (RR: 0.88, P = .60). Subanalyses based on the region of spine showed significantly lower length of stay in both cervical and lumbar surgeries implementing ERAS. Type of procedure showed a significantly lesser time-to-initiate mobilization in fusion surgeries using ERAS protocols compared with decompression. CONCLUSION: The present meta-analysis indicates that current literature supports ERAS implementation as a means of reducing care costs and safely accelerating hospital discharge for patients undergoing spine surgery.
Commentary: A Quantitative Assessment of Chat-GPT as a Neurosurgical Triaging Tool
Bydon, Mohamad , Johnson, Sarah E. , Katsos, Konstantinos, Johnson, Sarah E , Katsos, Konstantinos

Mayo Clinic

Neurosurgery | February 14, 2024 | Volume: 95 | Issue: 2 | Pages: e44-e44

10.1227/neu.0000000000002880 | PMID 38353559 Get It

Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Results of an International Randomized Controlled Trial (PEXIVAS)
Fussner, Lynn A. , Flores-Suárez, Luis Felipe , Cartin‐Ceba, Rodrigo , Specks, Ulrich , Cox, Gerard , Jayne, David , Merkel, Peter A. , Walsh, Michael , Moreland, Larry W. , Little, Mark A. , Johnson, David W. , Nachman, Patrick H. , Barratt, Jonathan , Bech, Jesper Nørgaard , Badve, Sunil V. , Jones, Rachel , Pavenski, Katerina , Cox, P Gerard , Jayne, David , Moreland, Larry W , Johnson, David W , Specks, Ulrich , Merkel, Peter A , Barratt, Jonathan , Birn, Henrik , Pavenski, Katerina

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | February 12, 2024 | Volume: 209 | Issue: 9 | Pages: 1141-1151

10.1164/rccm.202308-1426oc | PMID 38346237 Get It

Abstract Rationale Diffuse alveolar hemorrhage (DAH) is a life-threatening manifestation of antineutrophil cytoplasmic antibody–associated vasculitis (AAV). The PEXIVAS (Plasma Exchange and Glucocorticoids in Severe Antineutrophil Cytoplasmic Antibody–Associated Vasculitis) (NCT00987389) trial was the largest in AAV and the first to enroll participants with DAH requiring mechanical ventilation. Objectives Evaluate characteristics, treatment effects, and outcomes for patients with AAV with and without DAH. Methods PEXIVAS randomized 704 participants to plasma exchange (PLEX) or no-PLEX and reduced or standard-dose glucocorticoids (GC). DAH status was defined at enrollment as no-DAH, nonsevere, or severe (room air oxygen saturation of ≤ 85% as measured by pulse oximetry, or use of mechanical ventilation). Measurements and Main Results At enrollment, 191 (27.1%) participants had DAH (61 severe, including 29 ventilated) and were younger, more frequently relapsing, PR3 (proteinase 3)-ANCA positive, and had lower serum creatinine but were more frequently dialyzed than participants without DAH (n = 513; 72.9%). Among those with DAH, 8/95 (8.4%) receiving PLEX died within 1 year versus 15/96 (15.6%) with no-PLEX (hazard ratio, 0.52; confidence interval [CI], 0.21–1.24), whereas 13/96 (13.5%) receiving reduced GC died versus 10/95 (10.5%) with standard GC (hazard ratio, 1.33; CI, 0.57–3.13). When ventilated, ventilator-free days were similar with PLEX versus no-PLEX (medians, 25; interquartile range [IQR], 22–26 vs. 22–27) and fewer with reduced GC (median, 23; IQR, 20–25) versus standard GC (median, 26; IQR, 25–28). Treatment effects on mortality did not vary by presence or severity of DAH. Overall, 23/191 (12.0%) with DAH died within 1 year versus 34/513 (6.6%) without DAH. End-stage kidney disease and serious infections did not differ by DAH status or treatments. Conclusions Patients with AAV and DAH differ from those without DAH in multiple ways. Further data are required to confirm or refute a benefit of PLEX or GC dosing on mortality. Original clinical trial registered with www.clinicaltrials.gov (NCT00987389).